News | March 23, 2026
Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
